Biosimilars: An Approach to some Current Worldwide Regulation Frameworks (original) (raw)

REGULATORY CONSIDERATIONS OF BIOSIMILARS AND CLINICAL DILEMA OF THEIR USE

Sanamed Medical journal

View PDFchevron_right

Biosimilars: Regulatory Status and Implications across the World

Sandra Sigala

Journal of Pharmacovigilance, 2016

View PDFchevron_right

Regulatory challenges with biosimilars: an update from 20 countries

Desi Eka Putri

Annals of the New York Academy of Sciences, 2020

View PDFchevron_right

REFERENCE BIOLOGICAL MEDICINES ('ORIGINATORS') AND 'BIOSIMILARS': COMPETITION AND PATIENT PROTECTION

fausto massimino

View PDFchevron_right

Global regulatory landscape of biosimilars: emerging and established market perspectives

Hemant Malhotra

Biosimilars, 2015

View PDFchevron_right

Biosimilars: Impact of Biologic Product Life Cycle and European Experience on the Regulatory Trajectory in the United States

Ben Kaspar

Clinical Therapeutics, 2012

View PDFchevron_right

Comparing Originator Biologics and Biosimilars: A Review of the Relevant Issues

Giovanni Lapadula

Clinical Therapeutics, 2017

View PDFchevron_right

Regulatory Guidelines for Approval of Biosimilars in India, Europe, Brazil and China: A Comprehensive Overview

Meenakshi Chauhan

International Journal of Pharmacy and Pharmaceutical Sciences, 2016

View PDFchevron_right

Biosimilars in the European market

Joan Rovira

GaBI Journal, 2013

View PDFchevron_right

PANLAR consensus statement on biosimilars

sergio kowalski

Clinical Rheumatology, 2019

View PDFchevron_right

Biosimilars in Developed Economies: Overview, Status, and Regulatory Considerations

ANKITA BHARGAVA

Regulatory Toxicology and Pharmacology, 2019

View PDFchevron_right

REVIEW ARTICLE Biosimilars for Healthcare Professionals

Esteban Ortiz Prado

View PDFchevron_right

Roundtable on biosimilars with European regulators and medical societies, Brussels, Belgium, 12 January 2016

Andrea Laslop

Generics and Biosimilars Initiative Journal, 2016

View PDFchevron_right

Biosimilars and the Patent Law

Marek Świerczyński

Medicine, Law & Society, 2019

View PDFchevron_right

Review, Approval, and Marketing of Biosimilars in the United States Part 1: Safety and Regulatory Issues

Serena Purdy

2010

View PDFchevron_right

Biosimilars: from Technical to Pharmacoeconomic Considerations

Jean-louis Montastruc, Marta Gersberg

Thérapie, 2015

View PDFchevron_right

The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019

Desi Eka Putri

Biologicals, 2020

View PDFchevron_right

Biosimilars for Healthcare Professionals

Esteban Ortiz Prado

View PDFchevron_right

Biosimilars: Overview of current legislation and future prospects

JPR Solutions, Rishi Kant Pandey

View PDFchevron_right

Biosimilar medical products – licensing, pharmacovigilance and interchangeability

ljubica Suturkova

PRILOZI, 2016

View PDFchevron_right

The regulatory framework of biosimilars in the European Union

Paola Minghetti

Drug Discovery Today, 2012

View PDFchevron_right

Recommendations for the regulation of biosimilars and their implementation in Latin America

Valderilio F Azevedo

Generics and Biosimilars Initiative Journal, 2014

View PDFchevron_right

Practical Guidance on Biosimilars, With a Focus on Latin America

CECILIA BORLENGHI

View PDFchevron_right

Current Status of Biosimilar Regulations in the MENA Region

hadeia daas

International Journal of Research in Pharmaceutical Sciences, 2020

View PDFchevron_right

Market access of biosimilars: not only a cost issue

Gilbert Verbeken

Oncologie, 2011

View PDFchevron_right

The Science Behind Biosimilars: Entering a New Era of Biologic Therapy

Kamala Nola

Arthritis & rheumatology (Hoboken, N.J.), 2018

View PDFchevron_right

Review, Approval, and Marketing of Biosimilars in the United States

Serena Purdy

BioProcess International, 2010

View PDFchevron_right

Biosimilars regulation in United States and FDA approved biosimilars from 2015-2018

Aakash Deep

Applied Clinical Research, Clinical Trials and Regulatory Affairs, 2019

View PDFchevron_right

Biologicals and biosimilars: safety issues in Europe

Ricardo Baptista-Leite

Expert opinion on biological therapy, 2017

View PDFchevron_right